Roger E. Susi - 27 Oct 2025 Form 4 Insider Report for IRADIMED CORP (IRMD)

Role
CEO, PRESIDENT, CHAIRMAN, Director, 10%+ Owner
Signature
/s/ Roger E. Susi
Issuer symbol
IRMD
Transactions as of
27 Oct 2025
Transactions value $
-$388,429
Form type
4
Filing time
29 Oct 2025, 09:20:05 UTC
Previous filing
22 Oct 2025
Next filing
04 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Susi Roger E. CEO, PRESIDENT, CHAIRMAN, Director, 10%+ Owner C/O IRADIMED CORPORATION, 12705 INGENUITY DRIVE, ORLANDO /s/ Roger E. Susi 27 Oct 2025 0001613801

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRMD Common Stock Sale -$329K -4.24K -0.18% $77.56 2.33M 27 Oct 2025 By Phillip Susi 2008 Dynasty Trust F1, F2
transaction IRMD Common Stock Sale -$54.8K -700 -0.03% $78.33 2.33M 27 Oct 2025 By Phillip Susi 2008 Dynasty Trust F1, F3
transaction IRMD Common Stock Sale -$4.59K -58 0% $79.12 2.33M 27 Oct 2025 By Phillip Susi 2008 Dynasty Trust F1, F4
holding IRMD Common Stock 163K 27 Oct 2025 By Roger E. Susi Revocable Trust
holding IRMD Common Stock 2.06M 27 Oct 2025 By Matthew Susi 2008 Dynasty Trust F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $76.99 to $77.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $78.00 to $78.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $79.07 to $79.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.